Orion Oyj (OTCMKTS:ORINY) Sees Significant Growth in Short Interest

Orion Oyj (OTCMKTS:ORINY - Get Free Report) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 500 shares, a growth of 25.0% from the October 31st total of 400 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 5.0 days.

Orion Oyj Price Performance

Shares of Orion Oyj stock traded up $0.04 during trading hours on Monday, reaching $23.40. The stock had a trading volume of 700 shares, compared to its average volume of 491. The firm has a market capitalization of $6.61 billion, a PE ratio of 18.57 and a beta of 0.22. The stock's 50 day moving average is $25.32 and its 200 day moving average is $23.78. The company has a current ratio of 2.39, a quick ratio of 1.29 and a debt-to-equity ratio of 0.31. Orion Oyj has a twelve month low of $17.50 and a twelve month high of $28.55.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.63 earnings per share (EPS) for the quarter. Orion Oyj had a return on equity of 41.41% and a net margin of 23.01%. The firm had revenue of $517.97 million during the quarter. Equities analysts expect that Orion Oyj will post 1.26 earnings per share for the current fiscal year.

Orion Oyj Cuts Dividend

The company also recently disclosed a dividend, which was paid on Thursday, November 7th. Stockholders of record on Wednesday, October 16th were issued a $0.2405 dividend. The ex-dividend date of this dividend was Wednesday, October 16th. Orion Oyj's payout ratio is 26.98%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.